The clinical research behind Q-Actin®
Three peer-reviewed published studies. One US patent. One ingredient supplier in continuous US market presence since 2017. Here are the receipts.
Peer-Reviewed Clinical Trials
Nash et al. (2018) — Cucumis sativus extract vs. glucosamine-chondroitin in moderate knee osteoarthritis
Clinical Interventions in Aging, 2018:13, 2119–2126
122 adults aged 40–75 with moderate knee osteoarthritis were randomized to receive either 10 mg Q-Actin™ twice daily (= 20 mg/day total) or 1,350 mg glucosamine-chondroitin twice daily (= 2,700 mg/day) for 180 days. WOMAC pain scores were measured at Days 0, 30, 60, 90, 120, 150, and 180.
Why this matters: The most direct head-to-head test of Q-Actin® against the standard glucosamine-chondroitin dose. The 70.3% WOMAC reduction at 180 days is the headline result we cite — and it's from this trial, not a "5-day" study.
Read the full paper on PubMed Central →Hausenblas et al. (2025) — Cucumis sativus L. Supplementation on Mild to Moderate Joint Pain
Cureus 17(9): e93507. Published 29 September 2025. DOI: 10.7759/cureus.93507. ClinicalTrials.gov: NCT06246383. IRB: Sterling IRB protocol #11651.
80 adults (mean age 50.10) with a history (>3 months) of mild to moderate joint pain at Jacksonville University and University of North Florida were randomized to receive either 20 mg/day Q-Actin™ or placebo (rice protein 20 mg/day) for 60 days. CONSORT-compliant trial. Assessments at baseline, Day 15, Day 30, and Day 60.
Why this matters: The first published RCT specifically in adults with mild-to-moderate joint pain — broader population than the Nash trials, which focused on knee osteoarthritis. Same 20 mg/day dose. Placebo-controlled. The 31.79% WOMAC improvement at 60 days, and the 32.39% Pain Disability Index improvement, are the second pillar of the Vflex clinical evidence base after Nash 2018.
Read the full paper on Cureus →Nash et al. (2023) — Standardised idoBR1 Cucumber Extract in moderate osteoarthritis: a placebo-controlled study
Current Rheumatology Reviews, 2023 (DOI: 10.2174/1573397119666230206105703; PubMed 36748212)
101 adults with knee osteoarthritis were randomized into three arms: placebo, 20 mg Q-Actin daily, or 100 mg Q-Actin daily. The study tested whether the effect was dose-dependent. 91 completed the 180-day protocol.
Why this matters: Confirms that the 20 mg/day dose used in Vflex is a real, validated dose. Higher doses (100 mg) showed additional benefit, but 20 mg was clinically meaningful.
Read on PubMed →Lloyd et al. (2025) — Oral supplement in healthy older adults to support physical fitness and mental wellbeing
Frontiers in Nutrition, 12:1563999. Published 12 May 2025. DOI: 10.3389/fnut.2025.1563999. PubMed: 40421033. Trial registry: NCT05878847.
47 healthy middle-aged and older adults (ages 50–78; 15 men, 32 women) at Aberystwyth University were randomized to receive either 2 × Q-Actin gummies containing 10 mg Q-Actin daily (= 20 mg/day total) or matched placebo gummies for 12 weeks. Hand grip strength, finger dexterity (Nine-Hole Peg Test), Prime Diet Quality Score, sleep quality (Pittsburgh Sleep Quality Index), and urinary chemical composition were assessed.
Why this matters: This is the first peer-reviewed study of Q-Actin in healthy adults (not osteoarthritis patients), evaluating outcomes most consumers actually care about — sleep, finger dexterity, daily strength. It's also the trial behind the verified registry NCT05878847.
Read the full paper on PubMed →Safety & Toxicology
Kothari et al. (2018) — Q-Actin safety assessment
Toxicology Reports, 2018. PMC: PMC6224328.
Animal toxicology study evaluating Q-Actin safety profile in repeat-dose administration.
Why this matters: Vflex's daily dose is 20 mg in a 1 gummy serving. The no-observed-adverse-effect level (NOAEL) in animals — 1,000 mg/kg/day — is roughly 3,500× higher than the human daily dose on a body-weight basis. That's a substantial safety margin.
Read on PubMed Central →Mechanism of Action — How Q-Actin Works
Nash et al. (2015, 2020) — idoBR1 iminosugar reduces inflammatory responses
Cell-based research from PhytoQuest Limited establishing that the iminosugar amino acid idoBR1 — the active that Q-Actin® is standardized to (>1%) — modulates inflammatory markers in cellular assays.
Why this matters: Glucosamine-chondroitin works (when it works) by providing raw materials for cartilage. Q-Actin works through a different mechanism: signaling pathway modulation via the idoBR1 iminosugar. This is why a 20 mg dose can outperform 2,700 mg of glucosamine-chondroitin.
Patent & Industry Recognition
US Patent No. 9,326,977 B2 — Q-Actin®
Q-Actin® is protected by a US patent issued to IminoTech, Inc. in 2016. The patent covers the standardized cucumber extract delivering the active iminosugar idoBR1.
Q-Actin — NIE Healthy Aging Award Winner, 2021
Q-Actin® was recognized by Nutrition Industry Executive (NIE) in 2021 with the Healthy Aging Award category.
Manufacturing & Quality Assurance
Manufactured in an FDA-registered facility
Vflex is manufactured in an FDA-registered, cGMP-compliant facility (US FDA Registration No. 10063446198, valid through 31 December 2026).
Independent batch testing — FARE Labs Private Limited
Every batch is independently tested by FARE Labs (ISO-accredited). The current production batch (WG-251205) verified:
- Q-Actin (Cucumis sativus extract) per gummy: 22.4 mg (label spec NLT 20 mg) — exceeds label spec
- Heavy metals (arsenic, lead, mercury, cadmium): all below limit of quantification
- Pathogens (E. coli, Salmonella, Staph. aureus, Pseudomonas): all absent
- Total aerobic count, yeast & mould: each <10 cfu/g (spec NMT 1,000 / 300)
- Total sugar / added sugar: not detected — confirms sugar-free
